Alaunos Therapeutics faces a critical existential threat as its cash reserves have dwindled to $354,000, representing a near-total depletion from the $6.1 million held in 2023Q4.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.41 vs — | — vs — |
Q2 2026 May 15, 2026 | -$0.59 vs — | — vs — |
Q2 2026 Mar 31, 2026 | -$0.40+89.1% vs -$3.69 | $3,000+0.0% vs $3,000 |
Q4 2025 Nov 14, 2025 | -$0.55+88.8% vs -$4.90 | — vs — |
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) stock is surging on Tuesday with a massive session volume of 191.48 million compared to the average volume of 826.167 thousand, according to Benzinga Pro data.
Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension
Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team BOSTON, Oct. 13, 2026 /PRNewswire/ -- Paragon Labs (together with related entities, "Paragon"), a biotechnology company focused on the discovery and development of differentiated biologics, today announced that members of the former senior leadership team of Apogee Therapeutics ("Apogee") have joined Paragon. The expanded leadership team will support Paragon-discovered assets through clinical development and help build new companies around promising therapeutic candidates, starting with Velaris Therapeutics, a biotechnology company focused on developing therapies for pulmonary hypertension and related cardiopulmonary diseases.
Alaunos Therapeutics announces pricing of a public offering of common stock and pre-funded warrants to fund working capital and general corporate purposes.
Benchmark TCRT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alaunos Therapeutics, Inc. (TCRT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.74 | $4.25M | -1.06 | -50% | -133666.67% | -232.6% | — | |
| $8.04 | $3.59B | -16.62 | 60.6% | -58.19% | -29.71% | — | |
| $1.84 | $214.47M | -1.83 | -51.24% | -2619.64% | -73.92% | — | |
| $0.19 | $24.43M | -0.21 | 266.65% | -1655.35% | -108.72% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — |
Alaunos Therapeutics, Inc. (TCRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Alaunos Therapeutics, Inc. (TCRT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 29, 2026·SEC
May 26, 2026·SEC
May 18, 2026·SEC
Get notified when TCRT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alaunos Therapeutics, Inc. (TCRT) stock FAQ — growth, dividends, profitability & financials explained
Alaunos Therapeutics, Inc. (TCRT) reported $0.0M in revenue over the trailing twelve months. Revenue was $0.0M in fiscal year 2025. That is 190% more than the $0.0M of fiscal year 2001.
Alaunos Therapeutics, Inc. (TCRT) revenue fell by 50.0% over the trailing twelve months, compared with the twelve months before.
No. Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.0M over the trailing twelve months.
Alaunos Therapeutics, Inc. (TCRT) had a return on equity (ROE) of -232.6% over the trailing twelve months. A negative ROE means the company lost money over the period.
Alaunos Therapeutics, Inc. (TCRT) had negative free cash flow of $2.8M over the trailing twelve months.
